Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 12, 2014, Pages 1407-1414

  Oh, Y M ^a   Sheen, S S ^b   Park, J H ^b   Jin, U R ^b   Yoo, J W ^a   Seo, J B ^a   Yoo, K H ^c   Lee, J H ^d   Kim, T H ^e   Lim, S Y ^f   Yoon, H I ^g   Lee, J S ^a   Lee, S D ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d CHA University   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

Author keywords

COPD; Emphysema; Frequent exacerbation

Indexed keywords

ALBUMIN; PROTEIN; BIOLOGICAL MARKER; PLASMA PROTEIN;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE COUNT; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RESIDUAL VOLUME; RESPIRATORY AIRFLOW; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TOTAL LUNG CAPACITY; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DOWN REGULATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; QUESTIONNAIRE; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; STATISTICAL MODEL; TIME; VITAL CAPACITY;

AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; QUESTIONNAIRES; REPUBLIC OF KOREA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 84911449811     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0205     Document Type: Article

References (30)

1. Rabe K F, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
2. Mannino D M, Braman S: The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 502-506
3. Kim D S, Kim Y S, Jung K S, et al. Prevalence of chronic obstructive pulmonary disease in Korea: A population-based spirometry survey. Am J Respir Crit Care Med 2005; 172: 842-847.
4. Vanfleteren L E, Spruit M A, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
5. Vestbo J, Edwards L D, Scanlon P D, et al. Changes in forced expiratory volume in 1 secondover time in COPD. N Engl J Med 2011; 365: 1184-1192.
6. Hurst J R, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
7. HanMK, Kazerooni E A, Lynch D A, et al. Chronic obstructive pulmonary disease exacerbations in theCOPDGene study: Associated radiologic phenotypes. Radiology 2011; 261: 274-282.
8. Yoo J W, Hong Y, Seo J B, et al. Comparison of clinicophysiologic and CT imaging risk factors for COPD exacerbation. J Korean Med Sci 2011; 26: 1606-1612.
9. Bon J, Fuhrman C R, Weissfeld J L, et al. Radiographic emphysema predicts low bone mineral density ina tobaccoexposed cohort. Am J Respir Crit Care Med 2011; 183: 885-890.
10. Wouters E F, Postma D S, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasonetreatment in patients with COPD causes immediate and sustained disease deterioration: Arandomised controlled trial. Thorax 2005; 60: 480-487.
11. Wedzicha J A, Seemungal T A. COPD exacerbations: Defining their cause and prevention. Lancet 2007; 370: 786-796.
12. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-1448
13. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
14. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema insmokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-1108.
15. Madani A, Zanen J, de Maertelaer V, et al. Pulmonary emphysema: Objective quantification at multi-detector row CT-comparison with macroscopic andmicroscopic morphometry. Radiology 2006; 238: 1036-1043.
16. Gevenois PA, deMaertelaer V, De Vuyst P, et al. Comparison of computed density and macroscopic morphometry in pulmo- nary emphysema. Am J Respir Crit Care Med 1995; 152: 653-657.
17. Wood S A, Zerhouni E A, Hoford J D, et al. Measurement of three dimensional lung tree structures by using computed tomography. J Appl Physiol 1995; 79: 1687-1697.
18. Lee Y K, Oh Y M, Lee J H, et al. Quantitative assessment ofemphysema, air trapping, and airway thickening on computed tomography. Lung 2008; 186: 157-165.
19. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary functionand clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 44-52.
20. Wright J L, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011; 183: 50-58.
21. Bracke K R, D'Hulst A I, Maes T, et al. Cigarette smokeinduced pulmonary inflammation and emphysema areattenuated in CCR6-deficient mice. J Immunol 2006; 177: 4350-4359.
22. Bracke K R, D'Hulst A I, Maes T, et al. Cigarette smokeinduced pulmonary inflammation, but not airway remodelling, isattenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 2007; 37: 1467-1479.
23. Lee J H, Lee Y K, Kim E K, et al. Responses to inhaled longacting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010; 104: 542-549.
24. Patel B D, CoxsonH O, Pillai S G, et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 500-505.
25. Han M K, Agusti A, Calverley P M, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
26. Langsetmo L, Platt R W, Ernst P, et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177: 396-401.
27. Tashkin D P, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
28. O'Donnell D E, Parker C M. COPD exacerbations. Thorax 2006; 61: 354-361.
29. Ferreira I M, Brooks D, White J, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD000998.
30. Seemungal T A, Donaldson G C, Paul E A, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.